Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Columns

Critical result notifications at the point of care

January 2025—A clinical laboratory team at Ohio State University Wexner Medical Center took on a point-of-care testing problem common to other hospitals: documentation of critical result notification. At OSU, the documentation rate for point-of-care glucose critical result notification wasn’t high enough, and the team set out to raise it. It’s not sufficient to notify the physician or other provider. “You then have to prove you’re doing this, with documentation that the notification did in fact exist,” said Heather Stieglitz, PhD, D(ABCC), OSU co-director of clinical chemistry and toxicology, in an ADLM point-of-care testing session last summer.

From the President’s Desk

January 2025—If a much younger version of me could time-travel from the 1980s to today, that young man with his full head of hair would be hard-pressed to recognize modern pathology practice. Forty years ago, I was the junior member in a private practice group in New Orleans. There were five of us in the group, covering three hospitals, with four of us based at the largest facility and one pathologist at the second hospital. And one of us would occasionally travel to the third facility, a 60-bed small-town hospital about 80 miles away, to do prescheduled frozen sections. (Can you guess who got that responsibility? I became very familiar with long-distance driving at 6:00 AM.)

Clinical pathology selected abstracts

January 2025—The Food and Drug Administration published a letter in December 2021 detailing the risk of false-positive rapid plasma reagin test results when using Bio-Rad Laboratories’ BioPlex 2200 Syphilis Total and RPR kit to test people who had received the COVID-19 vaccine. It did not appear that Treponema pallidum particle agglutination assays were impacted by this issue. Several U.S. and Canadian blood collection organizations noted an unconfirmed increase in syphilis screening test reactivity rates, including unconfirmed repeat reactive rates, during the COVID-19 pandemic. In an investigation of this issue at the authors’ institution, which involved assessing syphilis testing records, the authors saw no change in nontreponemal testing results but did observe an incidental increase in test reactivity with the Beckman Coulter PK TP Microhemagglutination assay for detecting T. pallidum antibodies in 2020 and 2021. The authors conducted a study to explore the false-positive syphilis results using a different institutional assay and calculate the reactivity rate of syphilis screening with negative confirmatory testing from 2011 to 2023.

Anatomic pathology selected abstracts

January 2025—The World Health Organization’s diagnostic criteria for malignant phyllodes tumor may miss a significant number of such tumors that have metastatic potential, according to a study conducted by the authors. Therefore, the authors proposed new refined diagnostic criteria for malignant phyllodes tumor (MPT) and conducted a study to validate the refined criteria. Their validation study included 136 borderline phyllodes tumors (BoPTs) and MPT cases that were not included in the initial study. The authors evaluated tumor classifications based on the refined criteria and World Health Organization (WHO) criteria. The revised criteria for MPT were either stromal overgrowth and one or more other features, such as marked stromal cellularity, marked stromal cytologic atypia, or at least 10 mitoses per 10 high-power fields (10 mitoses/10 HPF), or it was absence of stromal overgrowth and one or more other features, such as marked stromal cytologic atypia, at least 10 mitoses/10 HPF, or permeative border.

Pathology informatics selected abstracts

January 2025—Mismatch repair deficiency is a critical biomarker for identifying patients who may benefit from immunotherapy, and accurate classification is essential to making personalized treatment decisions. The authors conducted a study in which they presented a deep learning-based approach for classifying mismatch repair deficiency (MMR-D) in endometrial cancer using whole slide images of H&E-stained slides. They employed a multiresolution ensemble learning model in which they processed whole slide images at three magnifications—2.5×, 5×, and 10×—using a combination of the deep-learning architectures InceptionResNetV2, EfficientNetB2, and EfficientNetB3. These networks were trained on a data set of 1,168 whole slide images from 325 patients, with each whole slide image labeled by a pathologist for MMR-D or MMR proficiency (MMR-P) based on IHC results for the key MMR proteins MLH1, MSH2, MSH6, and PMS2. The authors addressed color variability in the H&E slides using a CycleGAN-based network for color normalization, ensuring consistency across the data set.

Molecular pathology selected abstracts

January 2025—Autism spectrum disorder is a neurodevelopmental disorder that has behavioral and social effects. Average patient age at diagnosis is approximately five years old. However, symptoms can appear within the first 12 months of life. The symptoms and severity of autism spectrum disorder (ASD) vary widely. They can include difficulty with verbal and nonverbal societal interaction, limited or repetitive behaviors, varying intellectual abilities, and emotional dysregulation.

Q&A column

January 2025
Q. In a CAP TODAY Q&A (published in August 2024), it was stated that a correlation between an automated and manual white blood cell count is not needed in clinical practice. Does this apply to digital imaging analyzers, such as those from CellaVision and Scopio, as well? If correlations between digital and manual differentials are required, what are your recommendations for acceptability? Read answer.

Q. When we write pathology reports, especially for prostatectomies, our diagnostic lines are often long, per CAP checklist requirements. In some cases, we retrim the surgical margins to evaluate the distal margins and note in the diagnostic line that margins will be studied further. When we report the margin status after retrimming, we are compelled to amend the report, leading to a large and somewhat confusing report because our long diagnostic lines are repeated; the only difference is the single line of the surgical margin. Do you have recommendations for creating an amended versus addendum report and addressing how the report can be more focused for clinicians and patients? Read answer.

Newsbytes

January 2025—NYU Langone Health, a New York-based multisite system with six inpatient facilities, is implementing digital pathology—some would say lightning quick considering its size. Having started the project in mid-October with six subspecialties, pathology services expects to fully implement the digital distribution of images systemwide by this spring. “What we’ve seen at other systems is a very slow transition that sometimes never gets accomplished to 100 percent,” says Joan Cangiarella, MD, vice chair of clinical operations, Department of Pathology, NYU Grossman School of Medicine. “Here we presented it as, ‘We are all going to go digital.’”

Put It on the Board

January 2025—The biochemical genetics and molecular technologies laboratories at Mayo Clinic in Rochester, Minn., reported in a recently published study that individuals with a TPMT*1/*8 diplotype displayed reduced thiopurine 6-mercaptopurine metabolism between that of normal metabolizers and intermediate metabolizers, suggesting that TPMT*8 is a reduced-function allele. That allele is common among individuals of African or African American ancestry (approximately 2.3 percent minor allele frequency), the authors write, but is not included in genotyping recommendations owing to its uncertain function.

From the President’s Desk

December 2024—Maybe you’ve had this experience: A patient calls, scared to death. They can’t reach their doctor and they can’t make sense of their pathology report. What they want to know is simple: What does it mean for my health? Now that pathology reports and lab results are going to many patients at the same time they’re released to ordering physicians, we pathologists have a new audience to keep in mind. It’s a major change in who’s reading our reports and how familiar they are with the terminology we use. (Let’s face it: Our reports read like Greek even to our fellow physicians. They must be downright mystifying to patients.)

MARKETPLACE

TRENDING